ALK's partner Torii initiates final stage of clinical development of Japanese cedar SLIT
ALK's partner, Torii Pharmaceuticals has initiated a Phase II/III clinical development programme in Japan with the new allergy immunotherapy tablet for the treatment of Japanese cedar tree pollen allergy. The trial is expected to include approximately 1,000 subjects. September 02, 2014